Inventor · disambiguated record
Christoph Mahlert
Also filed as: MAHLERT CHRISTOPH
16 granted patents·19 pending applications·104 citations·filing 2010–2025
92Inventor score
Top patents by PatentIndex Score
35 records- 0195US11478554B2Antibody drug conjugates (ADCS) having enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Oct 25, 2022·5 cites·20 claims
- 0294US10973923B2Site specific homogeneous with KSP inhibitorsBayer Pharma AG·Filed 2016·Granted Apr 13, 2021·8 cites·37 claims
- 0394US10022453B2Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)Bayer Pharma AG·Filed 2014·Granted Jul 17, 2018·16 cites·39 claims
- 0492US11643469B2Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodiesBayer Pharma AG·Filed 2022·Granted May 9, 2023·1 cites·15 claims
- 0592US11123439B2Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groupsBayer Pharma AG·Filed 2016·Granted Sep 21, 2021·8 cites·51 claims
- 0692US10744205B2Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodiesBayer Pharma AG·Filed 2016·Granted Aug 18, 2020·9 cites·28 claims
- 0792US8992932B2Binder-drug conjugates (ADCs) and use thereofSEATTLE GENETICS INC·Filed 2012·Granted Mar 31, 2015·26 cites·12 claims
- 0891US11660351B2Antibody drug conjugates (ADCs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted May 30, 2023·5 cites·50 claims
- 0990US11001636B2Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodiesBayer Pharma AG·Filed 2017·Granted May 11, 2021·5 cites·15 claims
- 1089US11071788B2Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodiesBayer Pharma AG·Filed 2016·Granted Jul 27, 2021·6 cites·32 claims
- 1189US10485880B2Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodiesBayer Pharma AG·Filed 2015·Granted Nov 26, 2019·11 cites·29 claims
- 1287US11685714B2Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted Jun 27, 2023·3 cites·30 claims
- 1381US2023399411A1Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodiesBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1480US2025099600A1Active Metabolites of Kinesin Spindle Protein Inhibitor ConjugatesBayer Pharma AG·Filed 2024·Application pending·0 cites
- 1575US2023338559A1Antibody drug conjugates (adcs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1673US12059472B2Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBAYER AG·Filed 2017·Granted Aug 13, 2024·1 cites·15 claims
- 1771US2021230284A1Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodiesBayer Pharma AG·Filed 2021·Application pending·0 cites
- 1870US2024043379A1Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1968US12144865B2Antibody drug conjugates with enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Nov 19, 2024·0 cites·33 claims
- 2064US11806404B2Site specific homogeneous with KSP inhibitorsBayer Pharma AG·Filed 2021·Granted Nov 7, 2023·0 cites·18 claims
- 2161US2015030618A1Novel binder-drug conjugates (adcs) and use thereofSEATTLE GENETICS INC·Filed 2014·Application pending·0 cites
- 2261US2025361282A1Atrial natriuretic peptide engrafted antibodiesBAYER AG·Filed 2025·Application pending·0 cites
- 2359US12331094B2Atrial natriuretic peptide engrafted antibodiesBAYER AG·Filed 2019·Granted Jun 17, 2025·0 cites·18 claims
- 2457US2025188189A1Human antibodies against activated protein c and uses thereofCOAGULANT THERAPEUTICS CORP·Filed 2023·Application pending·0 cites
- 2557US2014127240A1Novel Binder-Drug Conjugates (ADCs) and Use of SameLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 2657US2013122024A1New binder-drug conjugates (adcs) and use thereofLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 2756US2013066055A1New binder-drug conjugates (adcs) and use thereofLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 2856US2016193359A1New binder-drug conjugates (adcs) and use thereofSEATTLE GENETICS INC·Filed 2016·Application pending·0 cites
- 2954US2015246136A1NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAMESEATTLE GENETICS INC·Filed 2015·Application pending·0 cites
- 3050US2020360531A1Antibody drug conjugates (adcs) with nampt inhibitorsBAYER AG·Filed 2019·Application pending·0 cites
- 3149US2021275686A1Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profileBAYER AG·Filed 2019·Application pending·0 cites
- 3247US2015023989A1New antibody drug conjugates (adcs) and the use thereofSEATTLE GENETICS INC·Filed 2012·Application pending·0 cites
- 3339US2018318438A1Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodiesBayer Pharma AG·Filed 2016·Application pending·0 cites
- 3436US2018185510A1Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodiesBayer Pharma AG·Filed 2016·Application pending·0 cites
- 3532US2012237496A1Protease variantsBIRKENFELD JOERG·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christoph Mahlert files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →